Les molécules courantes pour traiter
**2011* mutations of mortality: A closer look at Bendamustine in CLL: "Have I been too hard on Bendamustine? This alkylating agent is more than 30 years old and was discovered in communist East Germany, where it..."
**2011*mutations of mortality: Bendamustine: is it better?: "Bendamustine or Treanda is being seen as the new player on the block by many oncologists and is often regarded as the place to go when the p..."
*2009*mutations of mortality: Bendamustine trial: "A paper has appeared in the J Clin Oncol comparing Bendamustine with Chlorambucil in untreated patients with CLL. It shows Bendamustine to b..."
*2008*mutations of mortality: Bendamustine: Hype or Hope?: "A lot of fuss is being made about bendamustine (also known as Treanda). Because it is an alkylating agent with some of the properties of ..."
**2011*mutations of mortality: fludarabine v cladribine: "A new look at Cladribine has been published in Blood. It is perhaps a neglected drug, being very similar to fludarabine, which is usually pr..."
*2007*mutations of mortality: Fludarabine and prednisolone: "This is the comparison of two phase II trials at MDACC showing no benefit from adding prednisolone to fludarabine."
*2006*mutations of mortality: Fludarabine Combinations: "Today I want to evaluate an important new paper published in Cancer by Bill Wierda. http://www3.interscience.wiley.com/cgi-bin/abstract/1122..."
*2006*mutations of mortality: More on chlorambucil: "Although in the latest British CLL4 trials fludarabine and the higher dose of chlorambucil were indistinguishable in efficacy, fludarabine w..."
*2009*mutations of mortality: Chlorambucil rituximab for CLL: "This is an Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients ..."
*2009*mutations of mortality: Alemtuzumab at ASH: "Alemtuzumab is thought to be a superior monoclonal to rituximab for the treatment of CLL. The question ought then to be asked as to whether ..."
*2007*mutations of mortality: Consolidation therapy with Alemtuzumab: "This is another section on consolidation therapy to follow on from the section on bone marrow transplantion. An alternative approach with p..."
*2007*mutations of mortality: Campath: "I have been meaning to write something about Campath for some time. I first started using this monoclonal antibody before it had been humani..."
*2008*mutations of mortality: Do Statins make Rituximab ineffective?: "A few years ago a revolution took place in medical publishing with the introduction of open access journals freely available on line. Of cou..."
*2008*mutations of mortality: Rituxin and high white counts: "Many people are confused over why some doctors recommend reducing the white count before starting rituximab. Remember that rituximab was ori..."
*2006*mutations of mortality: Chlorambucil plus rituximab: "Don't read this if you are squeamish. As readers will know I have long been an advocate of chlorambucil plus rituximab as a logical regimen..."
*2006*mutations of mortality: Beta Glucan to enhance rituximab: "How rituximab kills CLL cells is not known for certain. It could do it by invoking direct apoptotic mechanisms. (Apoptosis = programmed cell..."
*2008*mutations of mortality: CLL: Immunochemotherapy: "Rituximab—the chimeric monoclonal anti-CD20—is only moderately active as a first-line agent in chronic lymphocytic leukaemia,[131] with an o..."
*2008*mutations of mortality: CLL Treatment: Purine analogues: "With the introduction of purine analogues, a class of drug better able to achieve complete remission in chronic lymphocytic leukaemia, the p..."
*2006*mutations of mortality: Steroids 3: "After a long interval, I want to complete this subject with an essay on how steroids are used in CLL. First, it goes without saying that wh..."
*2006*mutations of mortality: Monoclonal antibodies in CLL: "On May 4th this year the UKCLL Forum held a meeting in London. The topic was 'Monoclonal Antibodies in the Treatment of CLL' I have written ..."
Les molécules "en cours d'étude" pour traiter
*2009*mutations of mortality: OFAR: "I have been asked about OFAR (combined oxaliplatin, fludarabine, cytarabine and rituximab) There is one paper at ASH from MDACC on OFAR used..."
*2009*mutations of mortality: TRU016: "TRU-016 is described as “a single chain anti-CD37 Fc fusion molecule that displays pro-apoptotic and Fc-dependent cellular cytotoxicity acti..."
*2009*mutations of mortality: Ofatumumab at ASH: "Those expecting a load of new information on Ofatumumab (O) from ASH are likely to be disappointed. Only three papers have been accepted and..."
*2008*mutations of mortality: Hsp90 again: "Several people have asked about the status of heat shock protein 90, inhibition of which was thought of as a new way of treating the most ag..."
*2008*mutations of mortality: CLL: New agents: "A whole range of new therapeutic agents is in development, some of which are already in the clinic. Lenalidomide [163] might act by interfer..."
*2006*mutations of mortality: PARP inhibitors: "PARP inhibitors may offer the first really targeted therapy for CLL. Although monoclonal antibodies are thought of as targeted therapies th..."
*2006*mutations of mortality: Revlimid: "Revlimid is an analogue of thalidomide that has been developed as part of a research programme to separate the evil effects of thalidomide f..."
Aucun commentaire:
Enregistrer un commentaire